Accuray Incorporated (NASDAQ:ARAY) Shares Sold by Tudor Investment Corp ET AL

Tudor Investment Corp ET AL decreased its position in shares of Accuray Incorporated (NASDAQ:ARAY - Free Report) by 64.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 108,362 shares of the medical equipment provider's stock after selling 193,399 shares during the period. Tudor Investment Corp ET AL owned about 0.11% of Accuray worth $215,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in ARAY. Heartland Advisors Inc. increased its stake in shares of Accuray by 14.1% in the fourth quarter. Heartland Advisors Inc. now owns 3,824,750 shares of the medical equipment provider's stock worth $7,573,000 after buying an additional 472,800 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Accuray by 482.4% in the 4th quarter. JPMorgan Chase & Co. now owns 242,713 shares of the medical equipment provider's stock worth $481,000 after purchasing an additional 201,037 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Accuray by 6.8% in the 4th quarter. Renaissance Technologies LLC now owns 2,979,998 shares of the medical equipment provider's stock valued at $5,900,000 after purchasing an additional 189,414 shares in the last quarter. Walleye Capital LLC bought a new position in shares of Accuray during the fourth quarter worth about $300,000. Finally, Barclays PLC grew its stake in Accuray by 97.9% in the third quarter. Barclays PLC now owns 210,819 shares of the medical equipment provider's stock worth $380,000 after purchasing an additional 104,310 shares in the last quarter. Institutional investors and hedge funds own 64.08% of the company's stock.

Accuray Stock Performance

Shares of ARAY opened at $1.52 on Friday. The stock has a market capitalization of $155.79 million, a PE ratio of -30.30 and a beta of 1.30. The business's fifty day moving average price is $1.64 and its 200 day moving average price is $1.91. The company has a debt-to-equity ratio of 3.51, a current ratio of 1.62 and a quick ratio of 0.88. Accuray Incorporated has a 12-month low of $1.28 and a 12-month high of $2.95.

Accuray (NASDAQ:ARAY - Get Free Report) last posted its quarterly earnings results on Wednesday, April 30th. The medical equipment provider reported ($0.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.05) by $0.04. The company had revenue of $113.24 million for the quarter, compared to the consensus estimate of $101.53 million. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. Equities research analysts forecast that Accuray Incorporated will post 0.01 EPS for the current year.

Analysts Set New Price Targets

Separately, StockNews.com cut Accuray from a "buy" rating to a "hold" rating in a research note on Monday, May 5th.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.